Clinical Trial Update: Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating docetaxel and prednisone with or without OGX-011 in recurrent or metastatic prostate cancer after progression on hormone thera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• OGX-011 (custirsen)
• PREDNISONE (Prednisone)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED